Stocktwits on MSN
Regeneron’s drug combo fails to prove superiority over Merck’s Keytruda in melanoma
While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results